FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150192162> ?p ?o ?g. }

• W2150192162 endingPage "1093" @default.
• W2150192162 startingPage "1085" @default.
• W2150192162 abstract "The epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal growth factor (EGF) or transforming growth factor (TGF)-α, results in a conformational change in the receptor, which promotes homo- or heterodimerisation or oligomerisation with other EGFR molecules or other HER family members. Dimerisation results in the activation of intracellular tyrosine kinase, autophosphorylation and activation of signal transduction molecules, ultimately leading to cell cycle progression, reduced apoptotic capacity, angiogenesis and the metastatic phenotype. EGFR is expressed on normal human cells and also across a range of malignancies. Tumour EGFR expression correlates with poor prognosis and resistance to therapy. Cetuximab is a chimeric human:murine monoclonal antibody that binds competitively to the EGFR. Binding of the antibody to the EGFR prevents activation of the receptor by endogenous ligands; proliferation is reduced, apoptosis enhanced, and angiogenesis, invasiveness and metastasis reduced. Binding of cetuximab to the receptor also results in internalisation and degradation of the antibody–receptor complex, downregulating EGFR expression. EGFR has been recognised as an important therapeutic target in cancer. Other antibodies are also in development, and small molecular inhibitors of the tyrosine kinase domain are available. Cetuximab adds to the activity of radiotherapy in locoregional head and neck cancer, and when given with platinum-based chemotherapy is active in a proportion of patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck, as is cetuximab monotherapy. When cetuximab is added to cisplatin monotherapy in the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, the objective response rate is significantly improved and the hazard ratio for progression is 0.78. The most commonly reported adverse event associated with cetuximab treatment is an acneiform rash that occurred in 70 – 80% of patients treated with cetuximab. Presence of the characteristic rash is significantly associated with response and/or survival. It is possible that development of acneiform rash may become an important clinical prognostic marker. Serious cetuximab-related toxicities include hypersensitivity reactions. Thus, cetuximab is biologically active across a range of clinical scenarios in squamous cell carcinoma of the head and neck. Ongoing studies will be important in establishing its role in the routine management of head and neck cancer." @default.
• W2150192162 created "2016-06-24" @default.
• W2150192162 creator A5023000705 @default.
• W2150192162 date "2005-08-01" @default.
• W2150192162 modified "2023-10-18" @default.
• W2150192162 title "The role of cetuximab in the treatment of squamous cell cancer of the head and neck" @default.
• W2150192162 cites W1554880727 @default.
• W2150192162 cites W1570686199 @default.
• W2150192162 cites W1838340609 @default.
• W2150192162 cites W1939364580 @default.
• W2150192162 cites W1968172991 @default.
• W2150192162 cites W2002908987 @default.
• W2150192162 cites W2005204942 @default.
• W2150192162 cites W2010397777 @default.
• W2150192162 cites W2032359283 @default.
• W2150192162 cites W2033758838 @default.
• W2150192162 cites W2048454485 @default.
• W2150192162 cites W2058620780 @default.
• W2150192162 cites W2068125497 @default.
• W2150192162 cites W2070823688 @default.
• W2150192162 cites W2088658971 @default.
• W2150192162 cites W2097584581 @default.
• W2150192162 cites W2103134643 @default.
• W2150192162 cites W2129432386 @default.
• W2150192162 cites W2137600224 @default.
• W2150192162 cites W2169434055 @default.
• W2150192162 doi "https://doi.org/10.1517/14712598.5.8.1085" @default.
• W2150192162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16050785" @default.
• W2150192162 hasPublicationYear "2005" @default.
• W2150192162 type Work @default.
• W2150192162 sameAs 2150192162 @default.
• W2150192162 citedByCount "68" @default.
• W2150192162 countsByYear W21501921622012 @default.
• W2150192162 countsByYear W21501921622013 @default.
• W2150192162 countsByYear W21501921622014 @default.
• W2150192162 countsByYear W21501921622015 @default.
• W2150192162 countsByYear W21501921622016 @default.
• W2150192162 countsByYear W21501921622017 @default.
• W2150192162 countsByYear W21501921622018 @default.
• W2150192162 countsByYear W21501921622019 @default.
• W2150192162 countsByYear W21501921622020 @default.
• W2150192162 countsByYear W21501921622022 @default.
• W2150192162 crossrefType "journal-article" @default.
• W2150192162 hasAuthorship W2150192162A5023000705 @default.
• W2150192162 hasConcept C121608353 @default.
• W2150192162 hasConcept C126322002 @default.
• W2150192162 hasConcept C150109051 @default.
• W2150192162 hasConcept C170493617 @default.
• W2150192162 hasConcept C177917778 @default.
• W2150192162 hasConcept C184235292 @default.
• W2150192162 hasConcept C26375932 @default.
• W2150192162 hasConcept C2776530083 @default.
• W2150192162 hasConcept C2776833033 @default.
• W2150192162 hasConcept C2779438470 @default.
• W2150192162 hasConcept C2779998722 @default.
• W2150192162 hasConcept C42362537 @default.
• W2150192162 hasConcept C502942594 @default.
• W2150192162 hasConcept C526805850 @default.
• W2150192162 hasConcept C71924100 @default.
• W2150192162 hasConcept C86803240 @default.
• W2150192162 hasConcept C95444343 @default.
• W2150192162 hasConcept C97029542 @default.
• W2150192162 hasConceptScore W2150192162C121608353 @default.
• W2150192162 hasConceptScore W2150192162C126322002 @default.
• W2150192162 hasConceptScore W2150192162C150109051 @default.
• W2150192162 hasConceptScore W2150192162C170493617 @default.
• W2150192162 hasConceptScore W2150192162C177917778 @default.
• W2150192162 hasConceptScore W2150192162C184235292 @default.
• W2150192162 hasConceptScore W2150192162C26375932 @default.
• W2150192162 hasConceptScore W2150192162C2776530083 @default.
• W2150192162 hasConceptScore W2150192162C2776833033 @default.
• W2150192162 hasConceptScore W2150192162C2779438470 @default.
• W2150192162 hasConceptScore W2150192162C2779998722 @default.
• W2150192162 hasConceptScore W2150192162C42362537 @default.
• W2150192162 hasConceptScore W2150192162C502942594 @default.
• W2150192162 hasConceptScore W2150192162C526805850 @default.
• W2150192162 hasConceptScore W2150192162C71924100 @default.
• W2150192162 hasConceptScore W2150192162C86803240 @default.
• W2150192162 hasConceptScore W2150192162C95444343 @default.
• W2150192162 hasConceptScore W2150192162C97029542 @default.
• W2150192162 hasIssue "8" @default.
• W2150192162 hasLocation W21501921621 @default.
• W2150192162 hasLocation W21501921622 @default.
• W2150192162 hasOpenAccess W2150192162 @default.
• W2150192162 hasPrimaryLocation W21501921621 @default.
• W2150192162 hasRelatedWork W1837617056 @default.
• W2150192162 hasRelatedWork W184303960 @default.
• W2150192162 hasRelatedWork W1878584909 @default.
• W2150192162 hasRelatedWork W1964368483 @default.
• W2150192162 hasRelatedWork W1972655588 @default.
• W2150192162 hasRelatedWork W1995828194 @default.
• W2150192162 hasRelatedWork W2000204434 @default.
• W2150192162 hasRelatedWork W2037602535 @default.
• W2150192162 hasRelatedWork W2150192162 @default.
• W2150192162 hasRelatedWork W4213087687 @default.
• W2150192162 hasVolume "5" @default.
• W2150192162 isParatext "false" @default.
• W2150192162 isRetracted "false" @default.

• next